<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494182</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0940</org_study_id>
    <secondary_id>NCI-2010-00623</secondary_id>
    <nct_id>NCT00494182</nct_id>
  </id_info>
  <brief_title>Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer</brief_title>
  <official_title>A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the combination of carboplatin,
      paclitaxel, and sorafenib can help to control the disease in patients with head and neck
      cancer. The safety of this drug will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Sorafenib is a drug that is designed to block the function of important proteins in cancer
      cells. These proteins, when active, are in part responsible for the abnormal growth and
      behavior of cancer cells.

      Carboplatin and paclitaxel are designed to work by stopping the division of cancer cells.

      Study Drug Administration:

      If you are found to be eligible to take part in this study, you will begin receiving
      sorafenib, carboplatin, and paclitaxel.

      On Day 1, paclitaxel will be given through a needle in your vein over 3 hours, followed by
      carboplatin by vein over 30 minutes.

      On Days 2-19, you will take sorafenib by mouth or by stomach tube. You will take 2 tablets of
      sorafenib each morning, and again each evening. Sorafenib should be taken with about 1 cup (8
      ounces) of water on an empty stomach (either 1 hour before a meal or 2 hours after a meal).
      Sorafenib must be swallowed whole without chewing or prepared using instructions provided on
      the patient handout for preparing sorafenib as a liquid. If you miss a dose, you should skip
      it and take the next scheduled dose at the scheduled time. Every 21 days is called a study
      &quot;cycle&quot;.

      You may be given medications before receiving the study drugs to decrease the risk of nausea
      and allergic reaction.

      Study Visits:

      On Days 1, 8, and 15 of Cycle 1 you will have the following tests and procedures performed:

        -  You will have a physical exam.

        -  Blood (about 1-2 teaspoons) and urine will be collected for routine tests.

        -  You will have a performance status evaluation.

        -  Blood (about 1-2 tablespoons) will be drawn to check to see how well your blood clots.

      On Day 1 of Cycles 2 and beyond, you will have the following tests and procedures performed:

        -  You will have a physical exam, including measurement of vital signs (blood pressure,
           heart rate, temperature, and breathing rate).

        -  Blood (about 2 teaspoons) and urine will be collected for routine tests.

        -  You will have a performance status evaluation.

        -  Blood (about 1-2 teaspoons) will be drawn to check how well your blood clots.

      Every week for the first 6 weeks on study treatment, you will measure and record your blood
      pressure. The study staff will explain to you how to measure your blood pressure. The study
      doctor or research nurse will review the log at each clinic visit.

      On Day 1 of every odd cycle (Cycles 3 and 5), you will have a chest x-ray and CT or MRI scans
      to check the status of the disease. If your doctor thinks it is needed, you will also have a
      bone scan.

      Length of Study:

      You may receive up to 6 cycles of treatment with the 3 study drugs. However, you may continue
      receiving sorafenib for as long as you are benefitting. You will be taken off study early if
      the disease gets worse or intolerable side effects occur.

      Study Visits for Sorafenib Treatment Only:

      If you continue to receive sorafenib after you have finished with the 6 cycles of treatment
      with the 3 study drugs, you will take the sorafenib every day. You will have study visits
      every 8 weeks. At these visits, you will have the following tests and procedures performed:

        -  You will have a physical exam.

        -  Blood (around 2 teaspoons) and urine will be collected for routine tests.

        -  You will have a performance status evaluation.

        -  Blood (about 1-2 teaspoons) will be drawn to check how well your blood clots.

        -  You will have a chest x-ray and CT or MRI scan to check the status of the disease every
           2 cycles.

      End-of-Study Visit:

      At the end of study treatment, you will have the following tests and procedures performed:

        -  Your complete medical history will be recorded.

        -  You will have a physical exam.

        -  Blood (around 2 teaspoons) and urine will be collected for routine tests.

        -  Blood (about 1-2 teaspoons) will be drawn to check how well your blood clots.

        -  You will have a performance status evaluation.

        -  You will have a chest x-ray and CT or MRI scan to check the status of the disease.

        -  You will also have an ECG.

      This is an investigational study. Sorafenib is FDA approved for treatment of advanced renal
      cell cancer. Its use in this study, for this disease, is investigational. Carboplatin and
      paclitaxel are FDA approved and commercially available. Up to 42 patients will take part in
      this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2007</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival calculated from first day of receiving study drug until documented progressive disease or death due to any cause (if death occurs before progression). Patients without tumor progression or death at time of analysis, censored at date of last tumor assessment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib + Carboplatin + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib 400 mg orally twice daily on Day 2-19. Carboplatin 6 AUC intravenously (IV) over 30 Minutes on Day 1. Paclitaxel 200 mg/m^2 IV over 3 hours on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg by mouth twice daily on Day 2-19</description>
    <arm_group_label>Sorafenib + Carboplatin + Paclitaxel</arm_group_label>
    <other_name>BAY 43-9006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>6 area under the plasma drug concentration-time curve (AUC) by vein over 30 Minutes On Day 1</description>
    <arm_group_label>Sorafenib + Carboplatin + Paclitaxel</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>200 mg/m^2 by vein over 3 hours on Day 1</description>
    <arm_group_label>Sorafenib + Carboplatin + Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and the willingness to sign a written informed consent. A signed
             informed consent must be obtained prior to any study specific procedures.

          2. Patients must have cytologically or histologically proven recurrent or metastatic
             squamous cell cancer of the head and neck (SCCHN) from the primary tumor or lymph
             nodes of the oral cavity, larynx, oropharynx, or hypopharynx.

          3. No prior systemic chemotherapy for patients who present with metastatic disease. For
             patients with recurrent head and neck squamous cell carcinoma, prior chemotherapy is
             allowed if it was given as part of their definitive therapy. If patients have received
             prior combined modality therapy, they must be off therapy for at least 6 months.

          4. Age &gt;/= 18 years

          5. Patients must have at least 1 evaluable lesion. Lesions must be evaluated by computed
             tomography (CT) scan or magnetic resonance imaging (MRI)

          6. ECOG Performance Status (PS) of 0-1

          7. Controlled blood pressure (defined as systolic BP &lt;/= 140 mmHg and diastolic &lt;/= 85
             mmHg)

          8. Adequate bone marrow, liver &amp; renal function as assessed by the following laboratory
             requirements to be conducted w/in 7 days prior to start of first dose: Hemoglobin &gt;/=
             9.0 g/dL; Absolute neutrophil count (ANC) &gt;/= 1,500/mm^3; Platelet count &gt;/=
             100,000/mm^3; Total bilirubin &lt;/= 1.5 times the upper limit of normal (ULN);ALT and
             AST &lt;/= 2.5 x ULN (&lt;/= 5 x ULN for pts w/ liver involvement); INR &lt;/= 1.5 and PTT w/in
             normal limits

          9. Continued from Inclusion #8: Serum creatinine &lt;/= 1.5 ULN or creatinine clearance
             (CrCl) &gt;/= 45 mL/min (CrCl = Wt (kg) x (140-age)/72 x Cr level, female x 0.85) for pts
             w/ creatinine levels above institutional normal; Amylase &amp; lipase &lt; 1.5 x the ULN;
             Urinalysis (UA) must show less than 1+ protein in urine, or the pt will require a
             repeat UA. If repeat UA shows 1+ protein or more, a 24 hour urine collection will be
             required &amp; must show total protein &lt;/= 1000 mg/24 hour to be eligible

         10. Women of childbearing potential (not surgically sterilized or at least 2 years
             postmenopausal) must have a negative serum or urine pregnancy test performed within 7
             days prior to the start of treatment

         11. Women of childbearing potential and men must agree to use adequate contraception
             (abstinence; hormonal or barrier method of birth control) prior to study entry, for
             the duration of study participation and 3 months after end of treatment. Should a
             woman become pregnant while participating or the partner of a patient participating in
             this study becomes pregnant, they should inform their treating physician immediately.

        Exclusion Criteria:

          1. Cardiac disease: Congestive heart failure (CHF) &gt; Class II NYHA; active coronary
             artery disease (Myocardial infarction [MI] more than 6 months prior to study entry is
             allowed); or serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
             (beta blockers or digoxin are permitted)

          2. Uncontrolled hypertension defined as systolic blood pressure &gt; 140 mmHg or diastolic
             pressure &gt; 85 mmHg despite optimal medical management

          3. Known history of Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B
             or C

          4. Active clinically serious infections (i.e. patients currently taking antibiotics)(
             Grade 2 NCI-CTC Version 3.0)

          5. Evidence or history of central nervous system (CNS) disease, including primary brain
             tumors, seizures disorders, or any brain metastasis

          6. Thrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or
             pulmonary embolism. History of transient ischemic attack is allowed.

          7. Evidence or history of bleeding diathesis or coagulopathy

          8. History of/or current evidence of hemoptysis (bright red blood of Â½ teaspoon or more)

          9. Peripheral neuropathy &gt;/= Grade 2 (NCI-CTC Version 3.0)

         10. Anticancer chemotherapy or immunotherapy: Anticancer therapy is defined as any agent
             or combination of agents with clinically proven anticancer activity administered by
             any route with the purpose of affecting the cancer, either directly or indirectly,
             including palliative and therapeutic endpoints

         11. Radiotherapy to the target lesions within 3 weeks of start of first dose. Toxicities
             from radiotherapy must have resolved prior to start of first dose.

         12. No major surgery, open biopsy or significant traumatic injury within 4 weeks of start
             of first dose

         13. Serious, non-healing wound, ulcer, or bone fracture

         14. Granulocyte growth factors (G-CSF), within 3 weeks of study entry.

         15. Patients taking chronic erythropoietin are permitted provided no dose adjustment is
             made within 2 months prior to start of first dose.

         16. Pregnant or breastfeeding patients

         17. Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results

         18. Known or suspected allergy to any recombinant human antibodies, or compounds of
             similar chemical or biologic composition to sorafenib or any of the drugs in this
             study

         19. Any condition that is unstable or could jeopardize the safety or compliance of the
             patient in the study

         20. Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in the study EXCEPT cervical cancer in situ, treated basal cell
             carcinoma, superficial bladder tumors (Ta, Tis and T1) or any cancer curatively
             treated &gt; 3 years prior to study entry

         21. Known or suspected allergy to sorafenib (BAY 43-9006) or any agent given in
             association with this trial

         22. Any malabsorption conditions

         23. Therapeutic anticoagulation with warfarin, heparins, or heparinoids

         24. Patients taking phenytoin, carbamazepine, and Phenobarbital

         25. Patients taking rifampin and/or St. John's Wort

         26. Patients who are candidates for curative surgery or radiotherapy

         27. The patient has progressed within 6 months after completion of curative intent
             (definitive) treatment for localized/locoregionally advanced disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Blumenschein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2007</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>BAY 43-9006</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>SCCHN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

